No Data
Express News | Shanghai Micurx Pharmaceutical Co Ltd - Mrx-5 Generally Well Tolerated in Phase 1 Study
Express News | Micurx Announces the Successful Completion of Phase 1 Clinical Trial of Mrx-5 in Australia
MicuRx Announces the Successful Completion of Phase 1 Clinical Trial of MRX-5 in Australia
Shanghai Mengke Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Mushrooms Pharmaceuticals (688373.SH): MRX-5 has completed Phase I clinical trials in Australia and has achieved the expected goals.
Mingke Pharmaceutical (688373.SH) announced that the company has independently developed a new benzoxaborole antibacterial drug MRX-...
Medytox (688373.SH): The proposed investment amount in MicuRx Pharmaceuticals, Inc. is adjusted from $80 million to $60 million.
On October 9th, Geelong announced that Mengke Pharmaceuticals (688373.SH) plans to adjust the investment amount in MicuRx Pharmaceuticals, Inc. from $80 million to $60 million, with the contribution method still being cash investment. The company will, based on the funding situation, authorize management to implement the capital increase scheme in batches with its own or self-raised funds after completing the corresponding approval procedures.
No Data
No Data